NCT03788837View on ClinicalTrials.gov

ILOPROST in Septic Shock With Persistent Microperfusion Defects (I-MICRO)

PHASE3CompletedINTERVENTIONAL

Enrollment

240

Participants

Timeline

Start Date

July 3, 2019

Primary Completion Date

January 5, 2024

Study Completion Date

January 18, 2024

Conditions

Septic Shock Hyperdynamic

Interventions

DRUG

ILOPROST

The patient will receive treatment with intravenous ILOPROST therapy at a dose of 0.5ng/kg/min with increments of 0.5 ng/kg/min every 30 minutes up to a maximum posology of 1,5 ng/kg/min for 48h.

DRUG

NaCl

The patient will receive treatment with intravenous NaCl 0.9% (placebo-double blinded) with increments of infusion rate every 30 minutes for 48h

Trial Locations (1)

75010

Departement of Anesthesiology, Critical Care and Burn Unit; Saint-Louis hospital, Paris

All Listed Sponsors

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT03788837 - ILOPROST in Septic Shock With Persistent Microperfusion Defects (I-MICRO) | Biotech Hunter | Biotech Hunter